Trials / Conditions / Neuroendocrine Carcinomas

Neuroendocrine Carcinomas

9 registered clinical trials studyying Neuroendocrine Carcinomas — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America NCT07192991	Latin American Cooperative Oncology Group	—
Recruiting	A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer NCT07174583	IDEAYA Biosciences	Phase 1 / Phase 2
Recruiting	A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and NCT06041516	National Cancer Institute (NCI)	Phase 1
Suspended	A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers NCT05337735	M.D. Anderson Cancer Center	Phase 2
Completed	Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suf NCT02820857	Hospices Civils de Lyon	Phase 2
Completed	Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas NCT04122911	National Cancer Institute, Naples	Phase 2
Unknown	Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin NCT02695459	The Netherlands Cancer Institute	Phase 2
Completed	Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Pati NCT02457273	National Health Research Institutes, Taiwan	Phase 2
Unknown	Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tu NCT01203306	University of Turin, Italy	Phase 2